January 17, 2025 at 1:28 PM
Research shows: Rifaximin prophylaxis drives resistance to daptomycin, an unrelated, last-resort antibiotic
Rifaximin is used for hepatic encephalopathy in liver patients at high risk for infections, including VRE treated with daptomycin. The antibiotic was thought to pose a low resistance risk
Rifaximin is used for hepatic encephalopathy in liver patients at high risk for infections, including VRE treated with daptomycin. The antibiotic was thought to pose a low resistance risk
Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin - Nature
Rifaximin use, particularly in patients with liver cirrhosis, may be compromising the clinical use of daptomycin.
www.nature.com
March 5, 2025 at 11:33 AM
Research shows: Rifaximin prophylaxis drives resistance to daptomycin, an unrelated, last-resort antibiotic
Rifaximin is used for hepatic encephalopathy in liver patients at high risk for infections, including VRE treated with daptomycin. The antibiotic was thought to pose a low resistance risk
Rifaximin is used for hepatic encephalopathy in liver patients at high risk for infections, including VRE treated with daptomycin. The antibiotic was thought to pose a low resistance risk
BREAKING: rifaximin and simvastatin did not help people with decompensated cirrhosis
Congratulations to Elisa Pose
And congrats to @jama.com for getting this paper
#liversky t.co/BuPL0mURhl
Congratulations to Elisa Pose
And congrats to @jama.com for getting this paper
#liversky t.co/BuPL0mURhl
February 6, 2025 at 12:20 AM
BREAKING: rifaximin and simvastatin did not help people with decompensated cirrhosis
Congratulations to Elisa Pose
And congrats to @jama.com for getting this paper
#liversky t.co/BuPL0mURhl
Congratulations to Elisa Pose
And congrats to @jama.com for getting this paper
#liversky t.co/BuPL0mURhl
This is amazing and important work by Glen Carter and colleagues at the University of Melbourne
'Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin in Enterococcus'
www.nature.com/articles/s41...
'Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin in Enterococcus'
www.nature.com/articles/s41...
Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin - Nature
Rifaximin use, particularly in patients with liver cirrhosis, may be compromising the clinical use of daptomycin.
www.nature.com
October 24, 2024 at 7:09 AM
This is amazing and important work by Glen Carter and colleagues at the University of Melbourne
'Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin in Enterococcus'
www.nature.com/articles/s41...
'Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin in Enterococcus'
www.nature.com/articles/s41...
EX: Rifaximin, a common antibiotic for digestive issues costs ~$2,500-$3,000 via CVS Caremark.
Purchase from India for $70 WITH A PROFIT.
Purchase from India for $70 WITH A PROFIT.
January 16, 2025 at 12:55 AM
EX: Rifaximin, a common antibiotic for digestive issues costs ~$2,500-$3,000 via CVS Caremark.
Purchase from India for $70 WITH A PROFIT.
Purchase from India for $70 WITH A PROFIT.
In this clinical trial, addition of simvastatin plus rifaximin to standard therapy did not improve outcomes in patients with decompensated liver cirrhosis.
ja.ma/3CGXxqB
#MedSky
ja.ma/3CGXxqB
#MedSky
February 5, 2025 at 5:11 PM
In this clinical trial, addition of simvastatin plus rifaximin to standard therapy did not improve outcomes in patients with decompensated liver cirrhosis.
ja.ma/3CGXxqB
#MedSky
ja.ma/3CGXxqB
#MedSky
Development of off-target antibiotic resistance is always a worry.
Rifaximin is used as prophylaxis for hepatic encephalopathy in patients with cirrhosis.
This study indicates rifaximin may select out resistance to unrelated daptomycin
#IDSky #MicroSky #AMR 🩺🦠
www.nature.com/artic...
1/2
Rifaximin is used as prophylaxis for hepatic encephalopathy in patients with cirrhosis.
This study indicates rifaximin may select out resistance to unrelated daptomycin
#IDSky #MicroSky #AMR 🩺🦠
www.nature.com/artic...
1/2
Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin
Nature - Rifaximin use, particularly in patients with liver cirrhosis, may be compromising the clinical use of daptomycin.
www.nature.com
October 24, 2024 at 7:16 AM
Development of off-target antibiotic resistance is always a worry.
Rifaximin is used as prophylaxis for hepatic encephalopathy in patients with cirrhosis.
This study indicates rifaximin may select out resistance to unrelated daptomycin
#IDSky #MicroSky #AMR 🩺🦠
www.nature.com/artic...
1/2
Rifaximin is used as prophylaxis for hepatic encephalopathy in patients with cirrhosis.
This study indicates rifaximin may select out resistance to unrelated daptomycin
#IDSky #MicroSky #AMR 🩺🦠
www.nature.com/artic...
1/2
this is not to say the other things haven't helped, but taking the enzymes has been a game changer.
so to anyone in the future who is searching "SIBO" or "rifaximin" on bluesky.
spore based probiotics / digestive enzyme supplements, taken with meals. And take your multivitamins, and vitamin D.
so to anyone in the future who is searching "SIBO" or "rifaximin" on bluesky.
spore based probiotics / digestive enzyme supplements, taken with meals. And take your multivitamins, and vitamin D.
June 2, 2025 at 3:54 PM
this is not to say the other things haven't helped, but taking the enzymes has been a game changer.
so to anyone in the future who is searching "SIBO" or "rifaximin" on bluesky.
spore based probiotics / digestive enzyme supplements, taken with meals. And take your multivitamins, and vitamin D.
so to anyone in the future who is searching "SIBO" or "rifaximin" on bluesky.
spore based probiotics / digestive enzyme supplements, taken with meals. And take your multivitamins, and vitamin D.
🔎 Phase 2 trial of cirrhosis+ HE on lactose+rifaximin
capsule and enema FMT was
📍safe
📍⬇️ HE recurrence
📍regardless of dose, route or donor
#liversky
www.journal-of-hepatology.eu/article/S016...
capsule and enema FMT was
📍safe
📍⬇️ HE recurrence
📍regardless of dose, route or donor
#liversky
www.journal-of-hepatology.eu/article/S016...
January 13, 2025 at 3:30 PM
🔎 Phase 2 trial of cirrhosis+ HE on lactose+rifaximin
capsule and enema FMT was
📍safe
📍⬇️ HE recurrence
📍regardless of dose, route or donor
#liversky
www.journal-of-hepatology.eu/article/S016...
capsule and enema FMT was
📍safe
📍⬇️ HE recurrence
📍regardless of dose, route or donor
#liversky
www.journal-of-hepatology.eu/article/S016...
Recent study:⬆️ #daptomycin resist w #rifaximin.
But does this impact outcomes in #cirrhosis?
In VA & TriNetX we found no impact of rifaximin on dapt users on
🔑30-day mortality
🔑LT
🔑sepsis dev
🔑linezolid use
✅ @amergastroassn.bsky.social ➡️ pubmed.ncbi.nlm.nih.gov/40122471/ @absteward.bsky.social
But does this impact outcomes in #cirrhosis?
In VA & TriNetX we found no impact of rifaximin on dapt users on
🔑30-day mortality
🔑LT
🔑sepsis dev
🔑linezolid use
✅ @amergastroassn.bsky.social ➡️ pubmed.ncbi.nlm.nih.gov/40122471/ @absteward.bsky.social
March 24, 2025 at 1:27 PM
Recent study:⬆️ #daptomycin resist w #rifaximin.
But does this impact outcomes in #cirrhosis?
In VA & TriNetX we found no impact of rifaximin on dapt users on
🔑30-day mortality
🔑LT
🔑sepsis dev
🔑linezolid use
✅ @amergastroassn.bsky.social ➡️ pubmed.ncbi.nlm.nih.gov/40122471/ @absteward.bsky.social
But does this impact outcomes in #cirrhosis?
In VA & TriNetX we found no impact of rifaximin on dapt users on
🔑30-day mortality
🔑LT
🔑sepsis dev
🔑linezolid use
✅ @amergastroassn.bsky.social ➡️ pubmed.ncbi.nlm.nih.gov/40122471/ @absteward.bsky.social
Most viewed in the last 7 days from JAMA: The addition of simvastatin plus rifaximin to standard therapy does not improve outcomes in patients with decompensated liver cirrhosis.
https://ja.ma/4hYuPAm
https://ja.ma/4hYuPAm
February 15, 2025 at 12:00 PM
Most viewed in the last 7 days from JAMA: The addition of simvastatin plus rifaximin to standard therapy does not improve outcomes in patients with decompensated liver cirrhosis.
https://ja.ma/4hYuPAm
https://ja.ma/4hYuPAm
Maybe the patient was on rifaximin given liver failure for PSC, s/p SOT
@steventong.bsky.social
#IDSky
👇
www.nature.com/articles/s41...
@steventong.bsky.social
#IDSky
👇
www.nature.com/articles/s41...
Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin - Nature
Rifaximin use, particularly in patients with liver cirrhosis, may be compromising the clinical use of daptomycin.
www.nature.com
November 26, 2024 at 3:56 PM
Maybe the patient was on rifaximin given liver failure for PSC, s/p SOT
@steventong.bsky.social
#IDSky
👇
www.nature.com/articles/s41...
@steventong.bsky.social
#IDSky
👇
www.nature.com/articles/s41...
This is a brilliant paper in Nature from Ben Howden and colleagues: t.co/UTfCGiuPqc
Very convincing evidence that rifaximin drives daptomycin resistance in VRE
Look out for dapto resistance in patients with liver cirrhosis who have been on rifaximin
Very convincing evidence that rifaximin drives daptomycin resistance in VRE
Look out for dapto resistance in patients with liver cirrhosis who have been on rifaximin
https://rdcu.be/dXUDt
t.co
October 25, 2024 at 8:14 PM
This is a brilliant paper in Nature from Ben Howden and colleagues: t.co/UTfCGiuPqc
Very convincing evidence that rifaximin drives daptomycin resistance in VRE
Look out for dapto resistance in patients with liver cirrhosis who have been on rifaximin
Very convincing evidence that rifaximin drives daptomycin resistance in VRE
Look out for dapto resistance in patients with liver cirrhosis who have been on rifaximin
🧪 🦠
Paradigm Shift in Antibiotic Resistance: Low-risk no more.
Rifaximin attaches to RNA polymerase, hindering synthesis.
Mutations in RNA alter the cell membrane, reducing access to daptomycin.
Akin to a lock (RNA) deteriorating, one key (abx) fitting can impede the effectiveness of another.
Paradigm Shift in Antibiotic Resistance: Low-risk no more.
Rifaximin attaches to RNA polymerase, hindering synthesis.
Mutations in RNA alter the cell membrane, reducing access to daptomycin.
Akin to a lock (RNA) deteriorating, one key (abx) fitting can impede the effectiveness of another.
Rise of almost untreatable superbug linked to a common antibiotic | Drug resistance | The Guardian
amp-theguardian-com.cdn.ampproject.org
October 24, 2024 at 4:10 AM
🧪 🦠
Paradigm Shift in Antibiotic Resistance: Low-risk no more.
Rifaximin attaches to RNA polymerase, hindering synthesis.
Mutations in RNA alter the cell membrane, reducing access to daptomycin.
Akin to a lock (RNA) deteriorating, one key (abx) fitting can impede the effectiveness of another.
Paradigm Shift in Antibiotic Resistance: Low-risk no more.
Rifaximin attaches to RNA polymerase, hindering synthesis.
Mutations in RNA alter the cell membrane, reducing access to daptomycin.
Akin to a lock (RNA) deteriorating, one key (abx) fitting can impede the effectiveness of another.
🎥 Check out our animated video abstract on YouTube, where we dive into key findings from our study of testing a combination of low dose rifaximin+N-acetylcysteine (NAC) in an animal model: youtu.be/i9afwPsbqnU?...
Paper published in Scientific Reports journal: doi.org/10.1038/s415...
Paper published in Scientific Reports journal: doi.org/10.1038/s415...
Low dose rifaximin with N-acetylcysteine is superior to rifaximin alone in a rat model of IBS-D
YouTube video by Mark Pimentel and MAST Program
youtu.be
November 19, 2024 at 5:30 PM
🎥 Check out our animated video abstract on YouTube, where we dive into key findings from our study of testing a combination of low dose rifaximin+N-acetylcysteine (NAC) in an animal model: youtu.be/i9afwPsbqnU?...
Paper published in Scientific Reports journal: doi.org/10.1038/s415...
Paper published in Scientific Reports journal: doi.org/10.1038/s415...
📽️ Now online 🎧: lnkd.in/dJuMmsc4
Watch or listen to the newest EASL Studio Episode on “Rifaximin for Hepatic Encephalopathy: Balancing Benefits and Risks in the Era of Antimicrobial Resistance” from Wednesday, 26 Nov 2026.
#rifaximin #HepaticEncephalopathy #AntimicrobialResistance #cirrhosis #ACLF
Watch or listen to the newest EASL Studio Episode on “Rifaximin for Hepatic Encephalopathy: Balancing Benefits and Risks in the Era of Antimicrobial Resistance” from Wednesday, 26 Nov 2026.
#rifaximin #HepaticEncephalopathy #AntimicrobialResistance #cirrhosis #ACLF
November 27, 2025 at 3:20 PM
📽️ Now online 🎧: lnkd.in/dJuMmsc4
Watch or listen to the newest EASL Studio Episode on “Rifaximin for Hepatic Encephalopathy: Balancing Benefits and Risks in the Era of Antimicrobial Resistance” from Wednesday, 26 Nov 2026.
#rifaximin #HepaticEncephalopathy #AntimicrobialResistance #cirrhosis #ACLF
Watch or listen to the newest EASL Studio Episode on “Rifaximin for Hepatic Encephalopathy: Balancing Benefits and Risks in the Era of Antimicrobial Resistance” from Wednesday, 26 Nov 2026.
#rifaximin #HepaticEncephalopathy #AntimicrobialResistance #cirrhosis #ACLF
Simvastatin and rifaximin failed to improve outcomes for patients with decompensated liver cirrhosis compared to placebo.
by Pose E, Jiménez C (...) Ginès P et 47 al. in JAMA #MedSky
📖 read the article:
by Pose E, Jiménez C (...) Ginès P et 47 al. in JAMA #MedSky
📖 read the article:
Simvastatin and Rifaximin in Decompensated Cirrhosis
This randomized trial assesses the effect of 12 months of treatment with simvastatin plus rifaximin on acute-on-chronic liver failure incidence in patients with decompensated liver cirrhosis.
jamanetwork.com
February 14, 2025 at 4:32 PM
Simvastatin and rifaximin failed to improve outcomes for patients with decompensated liver cirrhosis compared to placebo.
by Pose E, Jiménez C (...) Ginès P et 47 al. in JAMA #MedSky
📖 read the article:
by Pose E, Jiménez C (...) Ginès P et 47 al. in JAMA #MedSky
📖 read the article:
The other thing this study might result in is a reassessment of the risk-benefit of rifaximin prophylaxis.
Encephalopathy risk vs #AMR risk. These are tough short vs medium term ethical dilemmas. 🩺🦠#IDSky
bsky.app/profile/gpo...
Encephalopathy risk vs #AMR risk. These are tough short vs medium term ethical dilemmas. 🩺🦠#IDSky
bsky.app/profile/gpo...
@gpollara.bsky.social on Bluesky
Development of off-target antibiotic resistance is always a worry.
Rifaximin is used as prophylaxis for hepatic encephalopathy in patients with cirrhosis.
This study indicates rifaximin may select out resistance to unrelated daptomycin
#IDSky #MicroSky #AMR 🩺🦠
https://www.nature.com/articles/s41586-024-08095-4
1/2
bsky.app
October 24, 2024 at 7:26 AM
The other thing this study might result in is a reassessment of the risk-benefit of rifaximin prophylaxis.
Encephalopathy risk vs #AMR risk. These are tough short vs medium term ethical dilemmas. 🩺🦠#IDSky
bsky.app/profile/gpo...
Encephalopathy risk vs #AMR risk. These are tough short vs medium term ethical dilemmas. 🩺🦠#IDSky
bsky.app/profile/gpo...
Most viewed in the last 7 days from JAMA: The addition of simvastatin plus rifaximin to standard therapy does not improve outcomes in patients with decompensated liver cirrhosis.
https://ja.ma/3EE33uQ
https://ja.ma/3EE33uQ
February 18, 2025 at 8:03 PM
Most viewed in the last 7 days from JAMA: The addition of simvastatin plus rifaximin to standard therapy does not improve outcomes in patients with decompensated liver cirrhosis.
https://ja.ma/3EE33uQ
https://ja.ma/3EE33uQ
December 20, 2024 at 10:26 AM
Rifaximin, used for liver disease, induces resistance to daptomycin, a last-resort antibiotic for VREfm. This raises significant concerns over rifaximin's prophylactic use. PMID:39443798, Nature 2024, @Nature doi.org/10.1038/s415...
Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin - Nature
Rifaximin use, particularly in patients with liver cirrhosis, may be compromising the clinical use of daptomycin.
doi.org
December 24, 2024 at 3:31 AM
Rifaximin, used for liver disease, induces resistance to daptomycin, a last-resort antibiotic for VREfm. This raises significant concerns over rifaximin's prophylactic use. PMID:39443798, Nature 2024, @Nature doi.org/10.1038/s415...
🧪 SAT-209 – #EASL2025
MNK6106 vs. rifaximin to treat #HepaticEncephalopathy - new Phase 2a data from Prof. @rajivjalan.bsky.social (UCL) explores safety, PK & ammonia-lowering potential. HE treatment innovation in motion! #Cirrhosis
MNK6106 vs. rifaximin to treat #HepaticEncephalopathy - new Phase 2a data from Prof. @rajivjalan.bsky.social (UCL) explores safety, PK & ammonia-lowering potential. HE treatment innovation in motion! #Cirrhosis
May 10, 2025 at 12:22 PM
🧪 SAT-209 – #EASL2025
MNK6106 vs. rifaximin to treat #HepaticEncephalopathy - new Phase 2a data from Prof. @rajivjalan.bsky.social (UCL) explores safety, PK & ammonia-lowering potential. HE treatment innovation in motion! #Cirrhosis
MNK6106 vs. rifaximin to treat #HepaticEncephalopathy - new Phase 2a data from Prof. @rajivjalan.bsky.social (UCL) explores safety, PK & ammonia-lowering potential. HE treatment innovation in motion! #Cirrhosis
SARS-CoV-2 Infection May Disrupt the Gut-Lung Axis
www.emjreviews.com/respiratory/...
www.emjreviews.com/respiratory/...
SARS-CoV-2 Infection May Disrupt the Gut-Lung Axis
A new review links SARS-CoV-2 infection driven gut dysbiosis to systemic inflammation and lung injury, proposing rifaximin as a gut focused option to reduce COVID-19 respiratory complications.
www.emjreviews.com
December 21, 2025 at 1:38 PM
SARS-CoV-2 Infection May Disrupt the Gut-Lung Axis
www.emjreviews.com/respiratory/...
www.emjreviews.com/respiratory/...
Eine Sibotherapie, z.B. mit Rifaximin, kann in einzelnen Fällen zu einer Verbesserung der ME-Symptomatik führen.
Ob es jedoch auch gegen Energie-Vampire hilft bleibt abzuwarten. Bestimmt läuft schon einen Phase-II-Studie 🤡
2/3
Ob es jedoch auch gegen Energie-Vampire hilft bleibt abzuwarten. Bestimmt läuft schon einen Phase-II-Studie 🤡
2/3
September 17, 2024 at 7:43 PM
Eine Sibotherapie, z.B. mit Rifaximin, kann in einzelnen Fällen zu einer Verbesserung der ME-Symptomatik führen.
Ob es jedoch auch gegen Energie-Vampire hilft bleibt abzuwarten. Bestimmt läuft schon einen Phase-II-Studie 🤡
2/3
Ob es jedoch auch gegen Energie-Vampire hilft bleibt abzuwarten. Bestimmt läuft schon einen Phase-II-Studie 🤡
2/3
Would LOVE to see Rifaximin listed.
US pharmacies charge ~$2,500-$3,000.
Its only $70 in India!!!
Hundreds of ppl suffering from SIBO cannot afford this drug.
US pharmacies charge ~$2,500-$3,000.
Its only $70 in India!!!
Hundreds of ppl suffering from SIBO cannot afford this drug.
January 1, 2025 at 8:08 PM
Would LOVE to see Rifaximin listed.
US pharmacies charge ~$2,500-$3,000.
Its only $70 in India!!!
Hundreds of ppl suffering from SIBO cannot afford this drug.
US pharmacies charge ~$2,500-$3,000.
Its only $70 in India!!!
Hundreds of ppl suffering from SIBO cannot afford this drug.